[WCSA - Wowtimes - Almanac Events & Achievements 2023] Highlights of 133-year journey of Santen Pharmaceutical, one of the world's leading ophthalmic pharmaceutical companies (1890)

31-07-2023

(wcsa.world) Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, specializing in ophthalmology, with its products having a leading share in the Japanese market and one of the leading ophthalmic companies worldwide, with products Products are sold in more than 50 countries.

Santen's main office is located in Kita Ward, Osaka City, Osaka Prefecture and 3 factories are in Ishikawa, Shiga and Nara Research and Development Center in Nara Prefecture.

Santen's 21 subsidiaries are located in the following countries: Japan, United States, Netherlands, Finland, United Kingdom, Spain, Switzerland, Italy, France, Germany, Sweden, China, Korea , Taiwan, India, Thailand, Malaysia, Philippines and Singapore.

 

The company's milestones:

- In 1890: Kenkichi Taguchi opened Taguchi Santendo pharmacy at 1- chome Kitahama, Higashi-ku (now Chuo-ku), Osaka-shi, Osaka. Santen’s main product at the time of establishment was a cold medication called Heburin-gan.

- In 1899: Launched Daigaku brand eye drops.

- In 1925: Santendo Co., Ltd. established.

- In 1935: Opening of Yodogawa Factory (later headquarters) in Shimoshinjo-cho, Higashiyodogawa-ku, Osaka.

- In 1945: Company name changed to Santendo Pharmaceutical Co., Ltd..

 - In 1958: Company renamed as Santen Pharmaceutical Co., Ltd. (current name).

- In 1962: Launched Japan’s first plastic eye drop container (Super Sante).

- In 1963: Thiola, an original antidote for liver treatment, launched in Japan.

- In 1965: Sante de U launched in Japan.

- In 1970: Antibiotic ophthalmic Ecolicin launched in Japan.

- In 1975: Anti-inflammatory ophthalmic Flumetholon launched in Japan.

- In 1977: Santen introduces a “bottle pack” production system, developed by Rommelag, a West German company. This enables container molding and solution filling in a single step. Santen thus becomes the first company to produce bottle-packed eye drops in Japan.

- In 1978: Santen begins marketing medical devices with the electroretinograph ROX-5T, produced by Heiwa Electric Industrial Co., Ltd. .

- In 1981: Timoptol, a treatment for glaucoma and ocular hypertension, launched in Japan.

- In 1982: Central Research Laboratories opened in Osaka.

- In 1985: Noto Plant opened and launched Sante 40 NE, an over-the-counter eye lotion for the treatment of blurred vision and eyestrain..

- In 1987: Anti-infective ophthalmic Tarivid launched in Japan.

- In 1992: Tahmin Santen Co., Ltd. established in Taiwan. Kary Uni, a treatment for early-stage senile cataracts, launched in Japan.

- In 1993: Subsidiary Santen Inc. established in the U.S.

- In 1994: Subsidiary Santen GmbH established in Germany

- In 1996: Opened Beijing Representative Office, Nara Research and Development Center and Shiga Plant.

- In 1997: Santen acquired Oy Star Ab, a Finnish ophthalmic pharmaceutical company, and establishes Santen Oy, the first overseas production base for Santen

- In 1999: Timoptol XE, a treatment for glaucoma and ocular hypertension, launched in Japan.

- In 2000: Santen Pharmaceutical Korea, Co., Ltd. and Guangzhou Representative Office established.

- In 2001: Santen acquired the U.S. firm Advanced Vision Science, Inc.

- In 2002: Sante de U plus E alfa, Sante 40V và Sante 40  launched in Japan.

- In 2004: U.S. sales partnership with Johnson & Johnson Vision Care, Inc. (currently VISTAKON pharmaceuticals, LLC) started.

- In 2005: Santen Pharmaceutical (China) Co., Ltd. established.

- In 2007: Suzhou Plant established in China. Sante Uruoi Contact a launched in Japan.

- In 2010: Diquas is the world’s first eye drop to take advantage of the pharmacological action of a P2Y2 receptor agonist, launched.

- In 2013: Ho Chi Minh Representative Office established.

- In 2014: Established subsidiaries in Switzerland, Italy, the U.K., Spain, Thailand, Malaysia and the Philippines. Launch of TAPCOM (tafluprost/timolol maleate), a treatment for glaucoma and ocular hypertension.

- In 2016: Established Santen Business Services Co., Ltd., Santen Eye Care Co., Ltd., Santen Pharmaceutical (Hong Kong) Limited.

- In 2017: Santen Limited Liability Company in Russia established.

- In 2019: Santen Canada Inc. in Canada established.

- In 2020: Entered into an Exclusive Licensing Contract with jCyte in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa.

- In 2022: DIQUAS LX Ophthalmic Solution 3% for dry-eye treatment dry-eye treatment launched in Japan.

- In 2023: Sante Medical Plus series launched in Japan.

According to santen.com, ja.wikipedia.org


Chris (collect) - World Creativity Science Academy